GW117, a novel derivate compound of agomelatine that acts as both a 5-HT2C receptor
antagonist and a MT1/MT2 receptor agonist, likely underlines the potent antidepressant …

GW117 is new melatonergic antidepressant being developed to show better antidepressant
action than agomelatine. The purpose of this study was to evaluate the toxicity and to …

The novel antidepressant agomelatine behaves as an agonist at melatonergic MT1 and MT2
receptors and as an antagonist at serotonin 5-HT2C receptors. This study investigated the …

Mechanism of action of agomelatine: a novel antidepressant exploiting synergy between
monoaminergic and melatonergic properties Page 1 CNS Spectrums (2014), 19, 207–212. © …

Agomelatine (AGO) is a new type of antidepressant with demonstrated antidepressant
effects and a unique modulating circadian rhythm action. However, AGO has hepatotoxicity …

In this work, nineteen analogues of Agomelatine were readily synthesized through structural
modification of the acetamide side-chain starting from the key common intermediate 2-(7 …

Agomelatine is a naphthalenic analogue of melatonin that is in clinical use for the treatment
of major depressive disorders. Interestingly, while agomelatine exhibits potent affinity for …

Agomelatine (S20098) is a novel antidepressant drug with melatonergic agonist and 5-
HT2C receptor antagonist properties, displaying antidepressant/anxiolytic-like properties in …

There are many potentials for the development of more effective, better tolerated, and more
rapidly acting antidepressants. As there is large prevalence of circadian dysfunction in …

Depressive disorders are of the highest socioeconomic and health-economic importance, as
they are the psychiatric disorders that most frequently cause psychosocial disability. Despite …